Lifeboat Foundation

Proteins are involved in every biological process, and use the energy in the body to alter their structure via mechanical movements. They are considered biological ‘nanomachines’ because the smallest structural change in a protein has a significant effect on biological processes. The development of nanomachines that mimic proteins has received much attention to implement movement in the cellular environment. However, there are various mechanisms by which cells attempt to protect themselves from the action of these nanomachines. This limits the realization of any relevant mechanical movement of nanomachines that could be applied for medical purposes.

The research team led by Dr. Youngdo Jeong from the Center for Advanced Biomolecular Recognition at the Korea Institute of Science and Technology (KIST, President Seok-Jin Yoon) has reported the development of a novel biochemical nanomachine that penetrates the cell membrane and kills the cell via the molecular movements of folding and unfolding in specific cellular environments, such as cancer cells, as a result of a collaboration with the teams of Prof. Sang Kyu Kwak from the School of Energy and Chemical Engineering and Prof. Ja-Hyoung Ryu from the Department of Chemistry at the Ulsan National Institute of Science and Technology (UNIST, President Yong Hoon Lee), and Dr. Chaekyu Kim of Fusion Biotechnology, Inc.

The joint research team focused on the hierarchical structure of proteins, in which the axis of the large structure and the mobile units are hierarchically separated. Therefore, only specific parts can move around the axis. Most existing nanomachines have been designed so that the mobile components and axis of the large structure are present on the same layer. Thus, these components undergo simultaneous movement, which complicates the desired control of a specific part.

Pushing The Boundaries Of Research To Build A Synthetic Kidney — Dr. Andrew McMahon, Ph.D. & Lewis Kleinberg, University Kidney Research Organization (UKRO)

The University Kidney Research Organization (UKRO — https://ukrocharity.org/) is a Los Angeles-based nonprofit charity, co-founded prominent entertainment attorney Kenneth Kleinberg, inspired by his personal journey with kidney disease, focused on supporting medical research and education related to the causes, treatment, and eradication of all forms of kidney disease.

Continue reading “Dr Andrew McMahon & Lewis Kleinberg — Pushing The Boundaries Of Research To Build A Synthetic Kidney” »

Artificial intelligence can ace medical exams and assess patient symptoms, but it doesn’t care whether you life or die.

Residual ridge resorption combined with dimensional loss resulting from tooth extraction has a prolonged correlation with early excessive inflammation. Nuclear factor-kappa B (NF-κB) decoy oligodeoxynucleotides (ODNs) are double-stranded DNA sequences capable of downregulating the expression of downstream genes of the NF-κB pathway, which is recognized for regulating prototypical proinflammatory signals, physiological bone metabolism, pathologic bone destruction, and bone regeneration. The aim of this study was to investigate the therapeutic effect of NF-κB decoy ODNs on the extraction sockets of Wistar/ST rats when delivered by poly(lactic-co-glycolic acid) (PLGA) nanospheres.

Michael Levin’s 2019 paper “The Computational Boundary of a Self” is discussed. The main topics of conversation include Scale-Free Cognition, Surprise & Stress, and the Morphogenetic Field. Michael Levin is a scientist at Tufts University; his lab studies anatomical and behavioral decision-making at multiple scales of biological, artificial, and hybrid systems. He works at the intersection of developmental biology, artificial life, bioengineering, synthetic morphology, and cognitive science.

🚩The Computational Boundary of a Self: Developmental Bioelectricity Drives Multicellularity and Scale-Free Cognition (can read in browser or download as pdf)
https://www.frontiersin.org/articles/10.3389/fpsyg.2019.02688/full.

Continue reading “What are Cognitive Light Cones? (Michael Levin Interview)” »

Scientists at MIT have unlocked a major breakthrough in the battle to reverse the effects of Alzheimer’s disease — one that shows “dramatic reductions” in neurodegeneration, a report stated. The exciting achievement came about after researchers were able to interfere with an enzyme typically found to be overactive in the brains of Alzheimer’s patients.

Called the nanofluidic drug-eluting seed (NDES), it delivers low-dose immunotherapy in the form of CD40 monoclonal antibodies (mAb).

In a significant groundbreaking medical development, researchers have created a tiny device, smaller than a grain of rice, to deliver drugs directly to the pancreatic tumor.

Nano-device uses less dosage to shrink cancer.

Continue reading “Novel device smaller than rice successfully shrinks pancreatic cancer” »

Finding ways to integrate electronics into living tissue could be crucial for everything from brain implants to new medical technologies. A new approach has shown that it’s possible to 3D print circuits into living worms.

There has been growing interest in finding ways to more closely integrate technology with the human body, in particular when it comes to interfacing electronics with the nervous system. This will be crucial for future brain-machine interfaces and could also be used to treat a host of neurological conditions.

But for the most part, it’s proven difficult to make these kinds of connections in ways that are non-invasive, long-lasting, and effective. The rigid nature of standard electronics means they don’t mix well with the squishy world of biology, and getting them inside the body in the first place can require risky surgical procedures.

The gene-editing system CRISPR-Cas9 which has revolutionized genetic engineering over the past decade involves cutting DNA strands which is a process that can be quite hard to control and can result in unwanted genetic changes. Now, thanks to researchers at the Massachusetts Institute of Technology and the University of California, San Francisco (UCSF), a new gene-editing technology called CRISPRoff can change that, according to a press release.

“Fast forward four years [from the initial grant], and CRISPRoff finally works as envisioned in a science fiction way,” says co-senior author Luke Gilbert. “It’s exciting to see it work so well in practice.”